Royalty Pharma’s Dazzling Debut Leads to Tepid Street Views

(Bloomberg) -- Coverage of Royalty Pharma Plc kicked off with a whimper instead of a bang after at least five analysts initiated with hold ratings and only three touted buy recommendations after on...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.